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Abstract: Biodegradable and bioresponsive polymer-based nanoparticles (NPs) can be used for
oligonucleotide delivery, making them a promising candidate for mRNA-based therapeutics. In this
study, we evaluated and optimized the efficiency of a cationic, hyperbranched poly(amidoamine)s-
based nanoparticle system to deliver tdTomato mRNA to primary human bone marrow stromal cells
(hBMSC), human synovial derived stem cells (hSDSC), bovine chondrocytes (bCH), and rat tendon
derived stem/progenitor cells (rTDSPC). Transfection efficiencies varied among the cell types tested
(bCH 28.4% ± 22.87, rTDSPC 18.13% ± 12.07, hBMSC 18.23% ± 14.80, hSDSC 26.63% ± 8.81) and
while an increase of NPs with a constant amount of mRNA generally improved the transfection
efficiency, an increase of the mRNA loading ratio (2:50, 4:50, or 6:50 w/w mRNA:NPs) had no impact.
However, metabolic activity of bCHs and rTDSPCs was significantly reduced when using higher
amounts of NPs, indicating a dose-dependent cytotoxic response. Finally, we demonstrate the
feasibility of transfecting extracellular matrix-rich 3D cell culture constructs using the nanoparticle
system, making it a promising transfection strategy for musculoskeletal tissues that exhibit a complex,
dense extracellular matrix.
Keywords: transfection; bioresponsive polymer-based nanoparticles; joint therapies; therapeutic
mRNA; biologicals
1. Introduction
Treatment of musculoskeletal disorders affecting the synovial joint, such as osteoarthri-
tis (OA) [1], gout [2], rheumatoid arthritis [3], scleroderma [4], or systemic lupus erythe-
matosus [5] is extremely challenging and effective therapies remain urgently needed. A
particular challenge is posed on the one hand by the complex structure of synovial joints,
due to the composition of different tissues, such as bone, cartilage, tendons and ligaments,
muscles and synovial membrane, and on the other hand by the tissue-specific properties,
such as the extent and types of extracellular matrix [6]. The current pharmacological
treatments for OA are often based on steroids (i.e., glucocorticoids) [7] and non-steroidal
anti-inflammatory drugs (NSAID) [8], which treat the symptoms but are not curative. The
various drugs currently in use are either administered systemically or locally, e.g., by
Biomedicines 2021, 9, 794. https://doi.org/10.3390/biomedicines9070794 https://www.mdpi.com/journal/biomedicines
Biomedicines 2021, 9, 794 2 of 17
infiltration of glucocorticoids. However, the efficacy of new treatment modalities, such as
recombinant proteins, is often hampered by the low penetration of substances into tissues
with dense extracellular matrices [9,10]. For example, recombinant proteins such as bone
morphogenetic proteins (BMPs) have been employed to enhance bone and cartilage repair.
It has been observed, however, that the primary limitation is often the failure of larger
molecules to reach deeper regions of the tissue [11]. In addition, cartilage and tendons are
not, or barely, vascularized and therefore, typically less amenable to treatments [12,13].
Further, the relatively short half-life and high clearance rates can limit the effectiveness of
protein-based therapies with the additional risk of an immune response to exogenously
produced proteins [14,15]. In this respect, new effective, targeted, and sustained treatments,
which can reach tissues and cells within the joint, or generally in the musculoskeletal
system, remain an unmet need.
A more recent class of recombinant proteins, i.e., chimeric proteins, aimed to produce
modified and engineered proteins with improved therapeutic function, e.g., a biologi-
cally active molecule with a short half-life can be paired with an inactive one, or certain
tissues can be targeted by fusing therapeutic or toxic proteins specific for the respective
tissue [16,17]. Mouse-human chimeric tumor necrosis factor-alpha (TNFα) blocking molec-
ular antibody (cA2, infliximab) [18] is used to treat inflammatory conditions, like Crohn’s
disease [19] and rheumatoid arthritis [20]. Nevertheless, as for conventional drug therapies
(e.g., small molecules), exogenous and sometimes repetitive administration is required for
all recombinant proteins. To overcome this issue, gene therapies have been developed to
enable therapeutic protein production in situ in the affected tissues. The first generation of
gene therapies relied on the use of viral vectors carrying DNA encoding the target protein
and its subsequent integration into the genomic DNA [21,22]. This type of therapy raised
safety concerns due to the impossibility to control intracellular behavior of the vector and
its cargo, mostly related to non-specific integration into the genome. The more recent intro-
duction of the CRISPR/Cas technology, where a specific gene can be targeted, modified,
turned on/off, has propelled gene therapy into a new era but still results in permanent
integration into the genome [23,24]. Therefore, alternative therapies are based on a highly
promising technology that uses in vitro-transcribed (IVT) mRNA to deliver genetic infor-
mation [25–27]. Currently, there are approximately 1750 trials for such therapies in various
fields, e.g., oncology, cardiology, pneumology, virology [28], and IVT mRNA is currently
being employed for the formulation of vaccines against coronavirus disease (COVID-19).
However, one drawback of naturally occurring mRNA species is their relative instability
and their immunogenicity. Therefore, different strategies have been developed to increase
the half-life of chemically produced mRNA therapeutics, e.g., by chemical modification of
the 5′-cap and a 3′ poly(A) tail or the use of N1-methyl-pseudouridine (ψ) in the open read-
ing frame (ORF) and untranslated regions (UTRs). In general, the delivery of mRNAs to
the cells is considered more effective and safer compared to previously used strategies (e.g.,
plasmids), since mRNA cannot be genetically integrated and acts in a transient manner [29].
For mRNA-based therapies to be efficacious, an appropriate delivery system is required,
which is not only essential for effective delivery of the active oligonucleotide compound but
can also impact the pharmacodynamics and pharmacokinetics. A majority of the delivery
modalities have made use of various viruses, raising similar concerns as for viral delivery
of DNA. Furthermore, viral vectors are known to spread out to other organs, which has al-
ready been shown for intra-articular injection [30]. Non-viral delivery of nucleic acids into
cells can be achieved with lipids (liposomes) or lipid nanoparticles (LNP) by fusion with
the cellular membrane [31–34]. However, although Lipofectamine (Invitrogen, Waltham,
USA) or similar lipid-based reagents achieve high transfection efficiencies in vitro, the
in vivo application is mostly not feasible due to their high cell toxicity [35,36]. Another
approach makes use of nanoparticles (NPs) as a delivery system. NPs resemble particles,
with a diameter of 1–1000 nm in at least one dimension [37], and these non-viral delivery
technologies make use of synthetic polymers. Overall, a suitable NP-based transfection
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method should demonstrate minimal cytotoxicity, result in high expression levels of the
gene-of-interest, and be highly reproducible.
In this study, we used polymeric hybrid constructs based on multifunctional poly(ami-
doamines), previously developed as nanoparticle carriers for intracellular delivery of
(oligo-) nucleotides [38–40]. The previously described linear poly(amidoamines) were
used as a polyplex for delivery of oligonucleotides. For the current study, the polymers
were hyperbranched and cross-linked to further increase the delivery efficacy and the
stability of the nanoparticles, with the aim to create a polymeric network that can be cross-
linked to form a particle. The cationic core of the nanoparticles allows efficient loading of
mRNAs by electrostatic interactions in aqueous solution without the need for proprietary
instrumentation. The use of these nanoparticles further allows scale-up as the materials
can be produced in bulk and formulated with any desired oligonucleotide payload for
different applications.
The objective of this study was to assess and optimize the nanoparticle: mRNA
formulation for effective mRNA delivery to primary cells present in joints. Local delivery
of loaded nanoparticles into the articular joint allows for targeting negatively charged
cells and tissues such as cartilage or tendon, potentially enhancing mRNA delivery and
treatment efficacy for joint-related diseases. Therefore, we used various cell types from
different species: human bone marrow stromal cells (hBMSC) and synovial derived stem
cells (hSDSC), which are cells commonly used in orthopedic tissue engineering approaches;
bovine chondrocytes (bCH), an abundant source of cells commonly used for studying
cartilage biology in 2D and 3D in vitro models; and rat tendon derived stem/progenitor
cells (rTDSPC), as rats are frequently used for studying tendon regeneration, allowing
translation of in vitro results to in vivo studies. Together, we demonstrate that the presented
NP-based delivery system has potential for mRNA-based treatment of musculoskeletal
and joint-related pathologies, paving the way for future pre-clinical investigations.
2. Materials and Methods
2.1. Nanoparticle Synthesis
Cystamine bis(acrylamide) was synthesized from acryloyl chloride (Sigma-Aldrich,
St. Louis, MO, USA) and cystamine HCl (Sigma-Aldrich, St. Louis, USA) as described
previously by Lin et al. [41]. Poly(amidoamine)s were synthesized by Michael-type poly-
merization of primary (or bis-secondary) amines linked with bis-acrylamides as described
previously by Lin et al. [41]. Branched PEI800 (2% w/w, Sigma-Aldrich, St. Louis, MO,
USA) was added to the reaction mixture and hyperbranched poly(amidoamine) was made.
This hyperbranched polymer was dissolved in water with photoinitiator Irgacure 2959
(Sigma-Aldrich, St. Louis, MO, USA) and emulsified in mineral oil (VWR chemicals, Rad-
nor, PA, USA) with 10% of surfactant ABIL EM 90 (Sigma-Aldrich, St. Louis, USA) using
ultrasonication. The emulsion was exposed to UV irradiation to crosslink polymers and
form the NPs. The NPs were dialyzed against water, freeze-dried, and stored in the freezer.
The size and zeta potential of the NPs were measured using Dynamic Light Scattering
(DLS) (Zetasizer Nano ZS, Malvern, Kassel, Germany).
The encapsulation of mRNA into NPs was verified with an agarose gel electrophoresis.
Therefore, free mRNA, 10 µL of 1.5 mg/mL NPs complexed with mRNA (2:50 w/w loading
ratio), and loaded NPs treated with 2 M 1,4-Dithiothreitol (DTT) containing 5 mg/mL
heparin were heated for 5 min at 60 ◦C and loaded on a 1% agarose gel. Electrophoresis
ran at 90 mA for 15 min.
2.2. mRNA Synthesis
Chemically modified mRNA (mRNA) was synthesized as previously described by
Kormann et al. [42]. In brief, the respective pDNA templates were subjected to in vitro
transcription using T7 RNA Polymerase (Thermo Fisher Scientific, Waltham, MA, USA)
with a predefined mix of natural and chemically modified ribonucleotides. To enhance
RNA stability, a m7G cap structure was added to the 5′ end of the transcript, while the 3′
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end was subjected to enzymatic polyadenylation of ~120 nucleotides. The mRNA product
was purified by ammonium-acetate precipitation and was re-suspended in water at the
desired concentration. Standard 260/280 nm ratio was determined on a NanoDrop2000C
spectrophotometer (Thermo Fisher Scientific, Waltham, USA) and mRNA integrity and size
were determined using a Standard Sensitivity RNA Analysis Kit on a Fragment Analyzer
(Advanced Analytical Technologies, Ankeny, IA, USA).
2.3. Cell Isolation
2.3.1. Bovine Chondrocytes (bCH) Isolation
Metacarpal joints of 6–12 months old calves were acquired from a local abattoir.
Joints were opened, cartilage chips were removed from subchondral bone and transferred
into prepared tubes containing sterile phosphate-buffered saline (PBS) with 10× peni-
cillin/streptomycin (P/S) (Gibco by Life Technologies, Waltham, MA, USA, #15140-122).
Cartilage chips were transferred into spinner flasks and washed three times for 15 min each
with PBS containing 1× P/S. Tissues were predigested for 1 h using 0.1% Pronase (Roche,
Basel, Switzerland; in DMEM + 1× P/S, sterile filtered), and then incubated with 600 U/mL
collagenase II (Worthington Biochemical) for 14 h at 37 ◦C, 5% CO2, 90% humidity. The next
day, Dulbecco’s Modified Eagle Medium (DMEM, Gibco by Life Technologies, Waltham,
MA, USA, #52100-021 + 3.7 g/L NaHCO3 + 0.1 g/L sodium pyruvate) containing fetal
bovine serum (FBS, Gibco by Life Technologies, Waltham, MA, USA, #10500) was added
to a final concentration of 10% FBS in the digested tissue solution. The contents of the
spinner flask were passed through a cell strainer (40 µm) into centrifugation tubes and
centrifuged at 565× g for 7 min. The pellet was resuspended and washed two more times
with complete medium. Cells were counted in a Neubauer cell chamber and seeded at
3000 cells/cm2. Bovine chondrocytes were grown in DMEM (Gibco by Life Technologies,
Waltham, MA, USA, #52100-021 + 3.7 g/L NaHCO3 + 0.1 g/L sodium pyruvate), 10% FBS,
1× P/S.
2.3.2. Isolation of Human Mesenchymal Stem Cells (hBMSC)
Bone marrow aspirates were obtained from patients undergoing spine surgery at
the Inselspital Bern. The Swiss Human Research Act does not apply to research that
involves anonymized biological material and/or anonymously collected or anonymized
health-related data. Therefore, this project did not need to be approved by the ethics
committee. General Consent which also covers anonymization of health-related data
and biological material was obtained. BMSC isolation was performed via Ficoll density
gradient centrifugation as described in Rothweiler et al. [43]. Human BMSC were cultured
in BMSC medium consisting of Minimum Essential Medium α-modification (Gibco by Life
Technologies, Waltham, MA, USA, #1200-063 + 2.2 g/L NaHCO3), 10% FBS (Sera Plus,
PAN-Biotech, Aidenbach, Germany, #3702-P121812), 1× P/S (Gibco by Life Technologies,
Waltham, MA, USA, #15140-122), 5 ng/mL basic fibroblast growth factor (bFGF; Fitzgerald,
Acton, MA, USA, #30R-AF015).
2.3.3. Isolation of Human Synovial-Derived Stem Cells (hSDSC)
Synovial membranes were obtained from patients after informed consent was given
(ethical approvals GTE-2002 and AN-EK-FRBRG-135/14). Cell isolation was performed
according to Kovermann et al. [44]. SDSC growth medium consisted of DMEM, 10% FBS
(Sera Plus, PAN-Biotec, Aidenbach, Germany), 1× P/S, 5 ng/mL bFGF.
2.3.4. Isolation of Rat Tendon Derived Stem and Progenitor Cells (rTDSPC)
Male Sprague Dawley rats (12 weeks old) were euthanized with an intracardiac
injection of pentobarbital under deep isoflurane anesthesia. Rat tendon-derived stem and
progenitor cells (rTDSPC) were isolated as follows: Achilles tendons were dissected under
sterile conditions, cut into small pieces, and digested overnight at 37 ◦C in 3 mg/mL
collagenase type II (Gibco by Life Technologies, Waltham, MA, USA, #17101015) in αMEM
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medium (Sigma-Aldrich, St. Louis, MO, USA, #M4526) containing 10% FBS (Sigma-Aldrich,
St. Louis, MO, USA, #F7524), 1× GlutaMax (Gibco by Life Technologies, Waltham, MA,
USA, #35050-038) and 1× P/S (Sigma-Aldrich, St. Louis, MO, USA, #P4333), subsequently
referred to as αMEM complete medium. The isolated cells were collected on the following
day, washed with complete medium and plated on a 175 cm2 cell culture flask. At 70–80%
confluency, cells were collected and prepared for cryopreservation according to standard
protocols.
2.4. Cell Culture
All cells were grown under standard cell culture conditions (37 ◦C, 5% CO2, 90%
humidity). Medium changes were performed every 2–3 days and cells were passaged
at 80% confluency using Trypsin-EDTA (Sigma-Aldrich, St. Louis, MO, USA). For the
transfection experiments, cells were used up to passage 4 and seeded at 15,000 cells/cm2
using their described respective growth medium. All experiments were performed in
monolayer culture in TC24 well plates with an area of 1.92 cm2 per well.
2.5. 3D Cultures
BCH pellets were created and cultured in chondrogenic medium consisting of DMEM-
HG, 1× ITS+ (Corning, Corning, NY, USA, #354352), 1× non-essential amino acids (Gibco
by Life Technologies, Waltham, MA, USA, #11140-035), 1× P/S, 50 µg/mL ascorbic acid
2-phosohate (Sigma, #A8960), 10−7 M dexamethasone with 10 ng/mL transforming growth
factor β (TGFβ; Fitzgerald, Acton, MA, USA, #30R-AT072). Briefly, monolayer expanded
bCH were detached and transferred into a 96-well V-bottom plate (Thermo Fisher Scientific,
Waltham, MA, USA, #612V96 + #64200) at a density of 0.2 × 106 cells/well. Plates were
centrifuged at 400× g for 5 min to collect cells at the bottom of the plates. Medium changes
were performed every 2–3 days. Pellets were cultured for 7 days before transfection.
Tendon-like constructs of rTDSPC were created according to Gehwolf et al. [45] and
transfected after 7 days of culture. Z-stacks of unfixed pellets and unfixed constructs
were acquired 24 h after transfection (LSM 800/710, Zeiss, Oberkochen, Germany). All
transfection experiments were performed in triplicate.
2.6. Delivery of mRNA Using Nanoparticles
Polymeric nanoparticles (NPs; 20Med Therapeutics, Leiden, The Netherlands) were
supplied in lyophilized form and were freshly reconstituted in 20 mM sterile HEPES buffer
(Gibco by Life Technologies, Waltham, MA, USA, #15630-056) at 3 mg/mL just prior to
the experiment. A solution of mRNA (A) was prepared in 20 mM sterile HEPES buffer
with the appropriate concentration and an equal volume of nanoparticle solution (B) was
set up. Then, the mRNA solution (A) was mixed with an equal volume of NP solution
(B) and the resulting solution (A + B) was incubated at room temperature for 15 min.
Complete growth medium appropriate for the respective cell type was added and NPs
were delivered to the cells in 24-well plates in a total volume of 0.6 mL/well. Imaging,
viability testing, and flow cytometry were performed 24 h after transfection of the cells
with mRNA-loaded NPs. Experiments were performed using chemically modified, ARCA
capped mRNA encoding tdTomato at the indicated concentrations. mRNAs were provided
by Ethris GmbH (Planegg, Germany).
2.7. Fluorescence Imaging and Live/Dead Staining
Transfection efficiency of tdTomato mRNA loaded NPs was evaluated by laser confocal
microscopy (Zeiss, Oberkochen, Germany, LSM700/710 or LSM 800) after 24 h. Transfected
cells were co-stained with 5 µM Calcein (Sigma-Aldrich, St. Louis, MO, USA, #17783) and
0.625 µg/mL DAPI (Sigma-Aldrich, St. Louis, USA, #D9542) for 30 min to discriminate
between live and dead cells [46].
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2.8. Metabolic Activity and Toxicity Screening
AlamarBlue assay (BioRad, Hercules, CA, USA, #BUF012A) was used to determine
metabolic activity 24 h after transfection. The medium was aspirated and cells were
washed once with PBS. AlamarBlue solution was prepared according to the manufacturer’s
instructions using the respective growth medium for each cell type and 100 µL were added
per well. After 4 h under standard cell culture conditions, the medium was transferred
into a 96-well white plate and the fluorescent signal was measured at λex560/λem590 nm.
Working solution only was used as minimally viable control. Wells were blanked with
average medium fluorescence and metabolic activity was determined by the percentage of
control cells treated only with HEPES buffer.
2.9. Flow Cytometry
Cells were washed with PBS, 100 µL/cm2 Trypsin-EDTA was added to each well and
incubated for 4 min at 37 ◦C. Cells from three technical replicates were pooled into round-
bottom tubes and centrifuged for 5 min at 400× g. The medium was aspirated, the pellet
was resuspended in 100 µL flow cytometry buffer (3% serum in PBS) and passed through a
35 µm cell strainer. Tubes were spun briefly to pass the cells through the strainer and kept
on ice until measurement was performed (BD FACSAria III Cell Sorter, BD Accuri C6 Plus
Flow Cytometer, Franklin Lakes, NJ, USA). Forward, side scatter, and laser voltage were
adjusted using untreated cells. Cells treated with unloaded NPs were used as a reference.
2.10. Statistics
Statistical analyses were performed using Graph Pad Prism software (version 5.04;
GraphPad Software, San Diego, CA, USA). One-way analysis of variation (ANOVA) ap-
plying the Dunnett’s Multiple Comparison test were used to test for differences between
the metabolic activity of the treatment groups, using untreated cells as control. Differences
in transfection efficiencies were analyzed using One-way analysis of variation (ANOVA)
applying the Tukey’s Multiple Comparison test or the Dunnett’s Multiple Comparison test
when testing against the lowest NP:mRNA-treatment group as a reference. A p-value < 0.05
was considered statistically significant.
3. Results
3.1. Nanoparticle Characterization
Ten µL of 1.5 µg/mL NPs loaded with mRNA (2:50 w/w ratio) were analyzed on an
agarose gel to confirm the encapsulation of mRNA. Loading mRNA in the NPs prevents
migration in the agarose gel. Samples were treated with 2 M DTT containing 5 mg/mL
heparin and incubated for 5 min at 60 ◦C to release the mRNA from the particles, which was
shown by migration of released mRNA in the agarose gel (Figure 1). The average NP size
determined by DLS was 82 ± 4 nm (Figure 2), the polydispersity index was 0.170 ± 0.009,
and the zeta potential 32 ± 3 mV (n = 3).
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Figure 1. Migration of mRNA in agarose gel. (1) Free mRNA; (2) mRNA loaded nanoparticles;
(3) mRNA released from nanoparticles with 5 M DTT containing 5 mg/mL heparin.
Figure 2. Particle size distribution measured by % intensity and particle diameter expressed in nanometer (d.nm; n = 3).
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3.2. Nanoparticle-Based mRNA Delivery to Different Cell Populations of Articular Joints
An initial experiment was performed, where a standard amount of 480 ng mRNA en-
coding for tdTomato was complexed with 12 µg NPs (2:50 w/w ratio mRNA:nanoparticle)
and delivered in a 24-well format to different musculoskeletal cell types; bCH, rTDSPC,
hBMSC, hSDSC, respectively (Figure 3). After 24 h, tdTomato mRNA-loaded NPs were
taken up by all tested cell types and resulted in a translation of the mRNA into func-
tional, fluorescent tdTomato, while NPs or mRNA alone did not result in any fluorescent
signal. Live/dead cell staining with calcein (live) and DAPI (dead) showed that the
nanoparticle-based delivery of mRNA did not impair the viability of cells (Figure 3A).
Flow cytometry analysis demonstrated a transfection efficacy of approximately 20% for
bCH (28.40% ± 22.86), rTDSPC (18.13% ± 12.07), hBMSC (18.23% ± 14.80), and hSDSC
(23.63% ± 8.81) (Figure 3B). The metabolic activity of the cells was determined using an
AlamarBlue assay 24 h after treatment of the cells. Neither the complexed NPs nor the NPs
alone had a negative effect on the metabolic activity of bCH (103.55% ± 10.93), rTDSPC
(103.28% ± 0.546), and hBMSC (84.82% ± 13.54), while hSDSC (57.65% ± 24.48) showed a
significant decrease in their metabolic activity (p < 0.05, Dunnett’s Multiple Comparison
test) when treated with 12 µg NPs only (Figure 3C).
Figure 3. Cell viability and transfection efficiency of different primary cells treated with tdTomato
mRNA-complexed nanoparticles (NPs). (A) Fluorescence images of bCH, rTDSPC, hBMSC, hSDSC
treated with 12 µg NPs complexed with 480 ng tdTomato mRNA (2:50 w/w ratio mRNA:NPs).
tdTomato-positive cells (red), dead cells stained with DAPI (blue), and live cells stained with Calcein
(green). Scale bar = 50 µm. (B) Transfection efficiency analyzed with flow cytometry shown as %
tdTomato-positive cells of the entire cell population (n = 3; ANOVA and Tukey’s Multiple Comparison
test). (C) Metabolic activity is shown as % metabolic activity relative to control cells treated with
HEPES buffer (n = 3; ANOVA and Dunnet’s Multiple Comparison test using untreated cells as
control). § used to indicate significance for rTDSPC, * for hSDSC; * p < 0.05, §§ p < 0.01, §§§ p < 0.001.
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3.3. Effect of Different mRNA:Nanoparticle Ratios on Transfection Efficiency and Cell Viability in
bCH and rTDSPC
To examine if different concentrations of NPs (with a constant mRNA amount) could
improve the transfection efficiency of bCH and rTDSPC without affecting their viability,
480 ng tdTomato mRNA was complexed with 6, 12, 24, and 36 µg NPs in 0.6 mL, resulting
in mRNA:nanoparticle w/w ratios of 2:25, 2:50, 2:100, and 2:150, respectively. As shown in
Figure 4A, increasing the amount of NPs resulted in an increased expression of tdTomato,
although the same amount of mRNA was used for complex formation. bCH showed a
significant increase of transfection efficiency when 12 µg of complexed NPs were used
(41.07% ± 19.68) in comparison to 6 µg NPs (9.47% ± 5.00; p < 0.05, Dunnett’s Multiple
Comparison test). For rTDSPC, transfection efficiency was highest when 24 µg of com-
plexed NPs were used (39.27%± 8.22; Figure 4B). A higher NP amount seemed detrimental,
as transfection efficiencies generally decreased. Further, a significant reduction of metabolic
activity was also evident when 24 µg (bCH 49.58% ± 13.22, rTDSPC 78.91% ± 17.79) or
more of the complexed NPs were used for mRNA delivery (p < 0.01 for bCH, p < 0.05 for
rTDSPC; Dunnett’s Multiple Comparison test), indicating a cytotoxic effect (Figure 4C). In
particular, 36 µg of complexed NPs resulted in significant cell death (bCH 26.5% ± 15.08;
rTDSPC 22.91% ± 0.30; p < 0.001, Dunnett’s Multiple Comparison test), as also indicated
by the bright-field microscopy.
Figure 4. Transfection efficiency and metabolic activity after treatment with varying amounts of
nanoparticles and constant mRNA. (A) Fluorescent microscopy and bright-field images of cells
treated with 6, 12, 24, or 36 µg nanoparticles (NPs) complexed with constant 480 ng tdTomato mRNA.
Scale bar = 50 µm. (B) Transfection efficiency analyzed with flow cytometry shown as % tdTomato-
positive cells of the total population (ANOVA with Dunnet’s Multiple Comparison test using 6 µg
NPs [2:25] as a reference; n = 3). (C) Metabolic activity determined by AlamarBlue assay. Shown
is % metabolic activity relative to control cells treated with HEPES buffer (ANOVA with Dunnet’s
Multiple Comparison test using untreated cells as reference; n = 3). § used to indicate significance for
rTDSPC, * for bCH. */§ p < 0.05, ** p < 0.01, ***/§§§ p < 0.001.
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3.4. Transfection Efficiency and Metabolic Cell Activity after Treatment with Increasing Amounts
of mRNA Complexed to 6 or 12 µg of Nanoparticles
As 6 and 12 µg of NPs resulted in no noticeable cytotoxicity, we next determined
the optimal mRNA:nanoparticle loading ratio in bCH and rTDSPC. Then, 6 or 12 µg of
NPs were complexed with an increasing amount of tdTomato-mRNA, resulting in a 2:50,
4:50, and 6:50 w/w loading ratio of mRNA:NPs. As expected, 6 µg of complexed NPs
generally resulted in a low number of tdTomato-positive cells, with only a minimal effect
observed for the increasing mRNA loading ratios (Figure 5A). This was also confirmed
by flow cytometry analysis, demonstrating a higher transfection efficacy when 12 µg of
NPs were used. Interestingly, the different mRNA ratios did not improve the transfection
efficiency. Overall, bCH showed a better transfection efficacy when compared to rTDSPC
(Figure 5B). The metabolic activity of bCH and rTDSPC was not affected by any of the
different mRNA:NP loading ratios tested (Figure 5C).
Figure 5. Optimization of mRNA:nanoparticle (NP) loading ratio (w/w). (A) Fluorescence and bright-
field images of bCH and rTDSPC treated with 6 or 12 µg nanoparticles and an mRNA loading ratio of
2:50, 4:50, or 6:50. Scale bar = 50 µm. (B) Transfection efficiency analyzed with flow cytometry shown
as % tdTomato-positive cells of the total population (ANOVA with Tukey’s Multiple Comparison
test; n = 3). (C) Metabolic activity shown as % relative to HEPES-treated control cells. (ANOVA with
Dunnet’s Multiple Comparison test using untreated cells as control; n = 3). § p < 0.05.
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3.5. Treatment of bCH and rTDSPC with the Optimal mRNA:Nanoparticle Loading Ratio of 2:50
The previously determined optimal complexing ratio of 2:50 (mRNA:NPs) was used
to further optimize the transfection efficiency for both cell types. Therefore, cells were
incubated for 24 h with an increasing absolute amount of mRNA-complexed nanoparticles,
ranging from 6, 12, 24 to 36 µg. By increasing the amount of loaded NPs, the transfection
efficiency could significantly be improved, particularly for rTDSPC (Figure 6A,B). Inter-
estingly, differences between the two cell types were observed for their metabolic activity.
Whereas no signs of cytotoxicity and good transfection efficiency were seen for rTDSPC if
treated with 24 µg of nanoparticles complexed with 960 ng of mRNA encoding tdTomato
(viability 88.59% ± 19.89), a significant drop in activity of bCH treatFigure 6C). For both
cell types, treatment with 36 µg of complexed NPs was detrimental (bCH ed with this
amount of NPs (54.17% ± 32.56; p < 0.05, Dunnett’s Multiple Comparison test) was evident
(13.99% ± 11.66, rTDSPC 39.41% ± 12.39; p < 0.001, Dunnett’s Multiple Comparison test).
As also a loss in metabolic activity was observed when 36 µg of unloaded NPs were used
(bCH 36.17% ± 13.55, rTDSPC 45.56% ± 16.52; p < 0.001, Dunnett’s Multiple Comparison
test), a cytotoxic effect elicited by the mRNA or the tdTomato protein can be excluded.
Proof-of-concept experiments using the mRNA:NPs ratio of 2:50 in different absolute
amounts for treatment of 3D constructs showed successful transfection of cells embedded
in a more complex matrix (Figure 7). An increased tdTomato signal was observed with
increased particle dose, which is in line with results obtained in 2D experiments.
Figure 6. Treatment of bCH and rTDSPC with increasing amounts of the optimal mRNA:nanoparticle
loading ratio 2:50. (A) Fluorescence and bright-field images of bCH and rTDSPC treated with
the different formulations. Scale bar = 50 µm. (B) Transfection efficiency analyzed with flow
cytometry shown as % tdTomato-positive cells of the total population (ANOVA with Dunnet’s
Multiple Comparison test using 6 µg NPs [2:25] as a reference; n = 3). (C) Metabolic activity
determined by Alamar Blue assay (ANOVA with Dunnet’s Multiple Comparison test using untreated
cells as reference; n = 3). § used to indicate significance for rTDSPC, * for bCH. */§ p < 0.05, §§ p < 0.01,
***/§§§ p < 0.001. (n = 3).
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Figure 7. Transfection of 3D constructs of bCH and rTDSPC with the optimal mRNA:nanoparticle ratio of 2:50 (w/w).
Representative Z-stacks of unfixed pellets and 3D tendon-like constructs demonstrating ability of the mRNA-loaded NPs to
transfect cells embedded in a dense, collagenous matrix.
4. Discussion
Our study showed that the used NPs can be employed for the intracellular delivery
of (oligo-) nucleotides. Moreover, we optimized the transfection efficiency by keeping the
NPs at a low concentration, while improving the amount of loaded mRNA.
Recently, new and promising modalities, such as therapeutic mRNAs, have been pro-
posed that could effectively allow the production of proteins in situ, eliciting an effective
physiological response [42]. To improve mRNA-delivery into target cells and tissues, we
used poly(amidoamine)-based NPs for the intracellular delivery of (oligo-) nucleotides
(Figure 1). NPs were improved for in vivo application by branching and cross-linking
the poly(amidoamines) [38]. The mRNA is taken up by the cells based on proton buffer-
ing functionalization during loaded NPs formation, and adhesion of resulting stabilized
nanoparticle-mRNA on the cell membrane that permits the release into the cytosol. Subse-
quently, as previously described by Philipps et al., due to the relatively high concentration
of glutathione in the cytosol, the disulfide bonds in the nanoparticle network become
rapidly cleaved by the thiol-disulfide exchange reaction, resulting in rapid disassembly
of the nanoparticle-cage, release of the mRNA payload into the cytosol, and subsequent
protein translation [47].
Generally, NPs can be broadly applied for oligonucleotide delivery, but it is of
paramount importance to optimize them specifically for the target cells and tissues with
different phenotypes. By using a set of primary cell types present in a synovial joint, we
observed that every cell type had a distinct capability to take up the NPs and/or translate
mRNA to protein; in our case, we used mRNA encoding for tdTomato, a trackable red
fluorescent translated protein, to evaluate the yield and efficiency of transfection. The
results demonstrate that although we used the same amount of mRNA in chondrocytes,
tendon-derived stem/progenitor cells, synovium stem cells, and bone marrow stem cells,
albeit from different species, the transfection and yield of tdTomato protein expression
were different among all cell types investigated (Figure 3). This could be explained by the
varying ability and extent to which extracellular matrix is produced in 2D culture, which
could interfere with the delivery of mRNAs using NPs [48–50]. Furthermore, we sought to
overcome this limitation by optimizing parameters like the quantity of mRNA, NPs, and
the effective ratio between them. With this aim, we evaluated the effect of increased NP
concentration during transfection while keeping the mRNA amount constant. We focused
our attention mainly on chondrocytes and tenocytes which are known to produce high
levels of collagen-rich extracellular matrix. Increased concentration of NPs (24 µg; w/w
ratio 2:100) showed a beneficial effect on the transfection yield; however, a concomitant
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increase in cytotoxicity was also evident (Figure 4). We hypothesize that the NPs may
become toxic on monolayer cells at high concentration due to the high binding or possible
interference with cationic charge on the cellular membrane. Subsequent membrane lysis
and mitochondrial or lysosomal damage have also been described in literature [51].
Although a high concentration of NPs theoretically allows greater mRNA uptake and
protein expression, the NPs themselves may significantly disturb the cell behavior. Thus,
we optimized the transfection efficiency by keeping the NPs at a constant low concentration,
while increasing the amount of loaded mRNA. As we did not observe an increase in reporter
protein production (Figure 5), we hypothesize that the NPs have a saturation level beyond
which it is no longer possible to load more nucleic acids. We therefore evaluated how
increasing the total amount of complexed NPs (ratio 2:50) impacts transfection efficiency
and hence the expression of tdTomato (Figure 6). Thereby, we demonstrated that it was
possible to introduce a higher amount of nucleic acids into those cells that produce a
high amount of positively charged matrix, resulting in an increased amount of tdTomato
expression, by using one single-dose treatment. Successful transfection of bCH in pellets
and rTDSPC in tendon-like constructs indicates that more abundant extracellular material
did not interfere with the delivery system (Figure 7) and a dose-dependent effect like it
was seen in monolayer cultures was also apparent. Hence, we conclude delivery of NPs is
feasible in native tissues rich in extracellular matrix.
4.1. Strength and Weakness of the Study
The developed NPs and mRNAs proved to be functional at optimized concentrations
in a 2D-cell culture setting. The transfection experiments performed on three-dimensional
constructs can be regarded as initial indicators that a richer matrix does not inhibit transfec-
tion. Further analysis using different methods will be necessary to evaluate performance of
the NP delivery system in a 3D environment. Demonstration of the ability of the mRNA:NP
complexes to penetrate the ECM and transfect cells embedded in their native matrices is
necessary to evaluate if the current formulation will also achieve satisfactory transfection
in organotypic culture or in vivo. Moreover, further evaluation of the NPs in terms of
biocompatibility and performance in vivo will be needed. However, the general feasibility
and optimization of loading ratios and doses shown by the in vitro data presented in this
study serve as an important basis for future experiments in 3D-in vitro/ex vivo and in vivo
settings. The high amount of matrix present in the tissues of interest, i.e., cartilage and
tendon, may help to further attenuate toxicity and will possibly allow the use of higher
NP dosages to increase transfection performance. This has been shown for other nanoma-
terials [52], cytotoxic agents [53], radiation [54] in 3D culture experiments, and for other
polymeric NPs in vivo [55].
4.2. Clinical Outlook
Drug delivery by NPs has several advantages: good penetration of biological mem-
branes, the possibility of targeted drug delivery, improved solubility of hydrophobic drugs,
and increased drug stability. In addition, the use of nanoparticle, compared to other
methods like Lipofectamine, offers the possibility to be freeze-dried and remain stable
over prolonged time periods. Furthermore, due to the nature of the material, specific
optimization for the type of targeted cells or tissue is possible to provide high performance
during transfection. In vitro studies have shown that NPs below 90 nm penetrate carti-
lage explants through their entire thickness, while larger NPs tend to accumulate in the
superficial layers [37]. In vivo experiments in healthy rats also showed that avidin, a NP
carrier, penetrates throughout articular cartilage within six hours and can remain there
for up to one week [56]. Indeed, it has been shown that the concentration of endogenous
hyaluronate in the synovial fluid is sufficient to associate with NPs and slow their oth-
erwise rapid clearance from the synovium [57]. Despite all these advantages, there are
also some disadvantages. For example, NPs can aggregate, they can be immunogenic,
and the solvent of the particles can cause cell toxicity [37]. Overall, however, it can be
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stated that the clinical application of NPs is still in its infancy, especially in relation to
the application of musculoskeletal diseases. Although there are some FDA-approved NP
therapies and several ongoing clinical trials, these are mainly investigating the treatment
of diseases such as cancer, infectious diseases, and vaccination or iron deficiency using
NPs. Currently, there are no clinical trials investigating the administration of NP for the
treatment of musculoskeletal diseases, particularly joint diseases such as OA [58].
Regarding the treatment approach with mRNA, in vivo studies have already shown
that intra-articular injection of nanomicelles carrying runt-related transcription factor 1
(RUNX1) mRNA increased cartilage anabolic markers and exogenous protein expression in
OA mouse models. The authors concluded that the progression of OA was greatly slowed
by the in situ delivery of RUNX1 mRNA [59], indicating that IVT mRNA therapy is a
promising approach to treat OA and other pathologies of the musculoskeletal system.
5. Conclusions
By keeping a low and well-defined ratio between mRNA and NPs, it is possible
to introduce nucleic acids in cells that produce a positively charged matrix, preserving
their quality, while inducing the translation of mRNA in complex proteins. Moreover, NP
transfection proved successful for various cell types present in the musculoskeletal system
and may be a promising method for tissues that exhibit a complex dense matrix. Our
observation and optimization of the NPs and mRNA dose and ratio will pave the way for
further applications. Local NP-based delivery of therapeutic mRNAs for the modulation of
OA will be further studied in vitro and in vivo.
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Abbreviations
bCH bovine chondrocytes
bFGF basic fibroblast growth factor
BMPs bone morphogenetic proteins
FBS fetal bovine serum
hBMSC human bone marrow stromal cells




NSAID non-steroidal anti-inflammatory drugs
OA osteoarthritis
ORF open reading frame
PBS phosphate-buffered saline
P/S penicillin/streptomycin
RUNX runt-related transcription factor
rTDSPC rat tendon derived stem/progenitor cells
TNFα tumor necrosis factor-alpha
TGFβ transforming growth factor β
UTR untranslated regions
References
1. Glyn-Jones, S.; Palmer, A.J.R.; Agricola, R.; Price, A.J.; Vincent, T.; Weinans, H.; Carr, A.J. Osteoarthritis. Lancet 2015, 386, 376–387.
[CrossRef]
2. Wallace, S.L.; Robinson, H.; Masi, A.; Decker, J.L.; Mccarty, D.J.; Yü, T.-F. Preliminary criteria for the classification of the acute
arthritis of primary gout. Arthritis Rheum. 1977, 20, 895–900. [CrossRef] [PubMed]
3. McInnes, I.B.; Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 2011, 365, 2205–2219. [CrossRef]
4. Gabrielli, A.; Avvedimento, E.V.; Krieg, T. Scleroderma. N. Engl. J. Med. 2009, 360, 1989–2003. [CrossRef] [PubMed]
5. Mok, C.; Lau, C. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 2003, 56, 481–490. [CrossRef] [PubMed]
6. Wu, G.; Siegler, S.; Allard, P.; Kirtley, C.; Leardini, A.; Rosenbaum, D.; Whittle, M.; D’Lima, D.D.; Cristofolini, L.; Witte, H.; et al.
ISB recommendation on definitions of joint coordinate system of various joints for the reporting of human joint motion—Part I:
Ankle, hip, and spine. J. Biomech. 2002, 35, 543–548. [CrossRef]
7. Savvidou, O.; Milonaki, M.; Goumenos, S.; Flevas, D.; Papagelopoulos, P.; Moutsatsou, P. Glucocorticoid signaling and os-
teoarthritis. Mol. Cell. Endocrinol. 2019, 480, 153–166. [CrossRef] [PubMed]
8. Ding, C. Do NSAIDs affect the progression of osteoarthritis? Inflammation 2002, 26, 139–142. [CrossRef]
9. Lee, C.M.; Maibach, H.I. Deep Percutaneous Penetration into Muscles and Joints. J. Pharm. Sci. 2006, 95, 1405–1413. [CrossRef]
10. Dedrick, R.L.; Flessner, M.F. Pharmacokinetic Problems in Peritoneal Drug Administration: Tissue Penetration and Surface
Exposure. J. Natl. Cancer Inst. 1997, 89, 480–487. [CrossRef] [PubMed]
11. Bessa, P.C.; Casal, M.; Reis, R.L. Bone morphogenetic proteins in tissue engineering: The road from the laboratory to the clinic,
part I (basic concepts). J. Tissue Eng. Regen. Med. 2008, 2, 1–13. [CrossRef]
12. Bajpayee, A.G.; Grodzinsky, A.J. Cartilage-targeting drug delivery: Can electrostatic interactions help? Nat. Rev. Rheumatol. 2017,
13, 183–193. [CrossRef] [PubMed]
13. Rai, M.F.; Pham, C.T. Intra-articular drug delivery systems for joint diseases. Curr. Opin. Pharmacol. 2018, 40, 67–73. [CrossRef]
[PubMed]
14. Kou, L.; Xiao, S.; Sun, R.; Bao, S.; Yao, Q.; Chen, R. Biomaterial-engineered intra-articular drug delivery systems for osteoarthritis
therapy. Drug Deliv. 2019, 26, 870–885. [CrossRef]
15. Larsen, C.; Østergaard, J.; Larsen, S.; Jensen, H.; Jacobsen, S.; Lindegaard, C.; Andersen, P.H. Intra-articular depot formulation
principles: Role in the management of postoperative pain and arthritic disorders. J. Pharm. Sci. 2008, 97, 4622–4654. [CrossRef]
16. Scallon, B.J. Chimeric anti-TNF-αmonoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune
effector functions. Cytokine 1995, 7, 251–259. [CrossRef]
17. Strohl, W. Chimeric Genes, Proteins. In Reference Module in Life Sciences; Elsevier: Amsterdam, The Netherlands, 2017. [CrossRef]
18. Knight, D.M.; Trinh, H.; Le, J.; Siegel, S.; Shealy, D.; McDonough, M.; Scallon, B.; Moore, M.A.; Vilcek, J.; Daddona, P.; et al.
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 1993, 30, 1443–1453.
[CrossRef]
19. Van Dullemen, H.M.; van Deventer, S.J.; Hommes, D.W.; Bijl, H.A.; Jansen, J.; Tytgat, G.N.; Woody, J. Treatment of Crohn’s disease
with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109, 129–135. [CrossRef]
Biomedicines 2021, 9, 794 16 of 17
20. Elliott, M.; Maini, R.; Feldmann, M.; Kalden, J.; Antoni, C.; Smolen, J.; Leeb, B.; Breedveld, F.; Macfarlane, J.; Bijl, J.; et al.
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in
rheumatoid arthritis. Lancet 1994, 344, 1105–1110. [CrossRef]
21. Tratschin, J.D.; Miller, I.L.; Smith, M.G.; Carter, B.J. Adeno-associated virus vector for high-frequency integration, expression, and
rescue of genes in mammalian cells. Mol. Cell. Biol. 1985, 5. [CrossRef]
22. Büning, H.; Perabo, L.; Coutelle, O.; Quadt-Humme, S.; Hallek, M. Recent developments in adeno-associated virus vector
technology. J. Gene Med. 2008, 10, 717–733. [CrossRef]
23. Knott, G.J.; Doudna, J.A. CRISPR-Cas guides the future of genetic engineering. Science 2018, 361, 866–869. [CrossRef] [PubMed]
24. Fellmann, C.; Gowen, B.G.; Lin, P.-C.; Doudna, J.A.; Corn, J.E. Cornerstones of CRISPR–Cas in drug discovery and therapy. Nat.
Rev. Drug Discov. 2017, 16, 89–100. [CrossRef] [PubMed]
25. Sahin, U.; Karikó, K.; Türeci, Ö. mRNA-based therapeutics—Developing a new class of drugs. Nat. Rev. Drug Discov. 2014, 13,
759–780. [CrossRef] [PubMed]
26. Dowdy, S.F. Overcoming cellular barriers for RNA therapeutics. Nat. Biotechnol. 2017, 35, 222–229. [CrossRef] [PubMed]
27. Kaczmarek, J.C.; Kowalski, P.; Anderson, D.G. Advances in the delivery of RNA therapeutics: From concept to clinical reality.
Genome Med. 2017, 9, 1–16. [CrossRef]
28. U.S. National Library of Medicine. Available online: https://www.clinicaltrials.gov/ct2/results?cond=&term=mRNA&cntry=
&state=&city=&dist= (accessed on 26 April 2021).
29. Weng, Y.; Li, C.; Yang, T.; Hu, B.; Zhang, M.; Guo, S.; Xiao, H.; Liang, X.-J.; Huang, Y. The challenge and prospect of mRNA
therapeutics landscape. Biotechnol. Adv. 2020, 40, 107534. [CrossRef]
30. Evans, C.H.; Ghivizzani, S.C.; Robbins, P.D. Gene Delivery to Joints by Intra-Articular Injection. Hum. Gene Ther. 2018, 29, 2–14.
[CrossRef]
31. Gao, X.; Huang, L. Cationic liposome-mediated gene transfer. Gene Ther. 1995, 2, 710–722.
32. Farhood, H.; Serbina, N.; Huang, L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer.
Biochim. Biophys. Acta (BBA) Biomembr. 1995, 1235, 289–295. [CrossRef]
33. Filipczak, N.; Pan, J.; Yalamarty, S.S.K.; Torchilin, V.P. Recent advancements in liposome technology. Adv. Drug Deliv. Rev. 2020,
156, 4–22. [CrossRef] [PubMed]
34. Samaridou, E.; Heyes, J.; Lutwyche, P. Lipid nanoparticles for nucleic acid delivery: Current perspectives. Adv. Drug Deliv. Rev.
2020, 154–155, 37–63. [CrossRef]
35. Masotti, A.; Mossa, G.; Cametti, C.; Ortaggi, G.; Bianco, A.; Del Grosso, N.; Malizia, D.; Esposito, C. Comparison of different
commercially available cationic liposome–DNA lipoplexes: Parameters influencing toxicity and transfection efficiency. Colloids
Surf. B Biointerfaces 2009, 68, 136–144. [CrossRef] [PubMed]
36. Tabar, M.S.; Hesaraki, M.; Esfandiari, F.; Samani, F.S.; Vakilian, H.; Baharvand, H. Evaluating Electroporation and Lipofectamine
Approaches for Transient and Stable Transgene Expressions in Human Fibroblasts and Embryonic Stem Cells. Cell J. 2015, 17,
438–450.
37. Colella, F.; Garcia, J.P.; Sorbona, M.; Lolli, A.; Antunes, B.; D’Atri, D.; Barré, F.P.; Oieni, J.; Vainieri, M.L.; Zerrillo, L.; et al.
Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-
modifying agents. J. Control. Release 2020, 328, 985–999. [CrossRef] [PubMed]
38. Lin, C.; Zhong, Z.; Lok, M.C.; Jiang, X.; Hennink, W.E.; Feijen, A.J.; Engbersen, J.F.J. Novel Bioreducible Poly(amido amine)s for
Highly Efficient Gene Delivery. Bioconjug. Chem. 2007, 18, 138–145. [CrossRef]
39. Lin, C.; Engbersen, J.F. Effect of chemical functionalities in poly(amido amine)s for non-viral gene transfection. J. Control. Release
2008, 132, 267–272. [CrossRef] [PubMed]
40. Lin, C.; Lammens, T.; Zhong, Z.; Gu, H.; Lok, M.; Jiang, X.; Hennink, W.; Feijen, J.; Engbersen, J. Disulfide-containing poly
(β-amino ester)s for gene delivery. J. Control. Release 2006, 116, e79–e81. [CrossRef]
41. Lin, C.; Zhong, Z.; Lok, M.C.; Jiang, X.; Hennink, W.E.; Feijen, J.; Engbersen, J.F. Linear poly(amido amine)s with secondary and
tertiary amino groups and variable amounts of disulfide linkages: Synthesis and in vitro gene transfer properties. J. Control.
Release 2006, 116, 130–137. [CrossRef]
42. Kormann, M.S.D.; Hasenpusch, G.; Aneja, M.K.; Nica, G.; Flemmer, A.W.; Herber-Jonat, S.; Huppmann, M.; E Mays, L.; Illenyi,
M.; Schams, A.; et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol.
2011, 29, 154–157. [CrossRef] [PubMed]
43. Rothweiler, R.; Basoli, V.; Duttenhoefer, F.; Kubosch, D.; Schmelzeisen, R.; Johnstone, B.; Alini, M.; Stoddart, M.J. Predicting and
Promoting Human Bone Marrow MSC Chondrogenesis by Way of TGFβ Receptor Profiles: Toward Personalized Medicine. Front.
Bioeng. Biotechnol. 2020, 8, 618. [CrossRef]
44. Kovermann, N.J.; Basoli, V.; Della Bella, E.; Alini, M.; Lischer, C.; Schmal, H.; Kubosch, E.J.; Stoddart, M.J. BMP2 and TGF-β
Cooperate Differently during Synovial-Derived Stem-Cell Chondrogenesis in a Dexamethasone-Dependent Manner. Cells 2019,
8, 636. [CrossRef] [PubMed]
45. Gehwolf, R.; Spitzer, G.; Wagner, A.; Lehner, C.; Weissenbacher, N.; Tempfer, H.; Traweger, A. 3D-Embedded Cell Cultures to
Study Tendon Biology. Methods Mol. Biol. 2019, 2045, 155–165. [CrossRef] [PubMed]
46. Martin, R.; Leonhardt, H.; Cardoso, M.C. DNA labeling in living cells. Cytom. Part A 2005, 67A, 45–52. [CrossRef] [PubMed]
Biomedicines 2021, 9, 794 17 of 17
47. Phillips, D.J.; Patterson, J.; Oreilly, R.; Gibson, M. Glutathione-triggered disassembly of isothermally responsive polymer
nanoparticles obtained by nanoprecipitation of hydrophilic polymers. Polym. Chem. 2014, 5, 126–131. [CrossRef]
48. Dessau, W.; Vertel, B.M.; Von Der Mark, H. Extracellular matrix formation by chondrocytes in monolayer culture. J. Cell Biol.
1981, 90, 78–83. [CrossRef] [PubMed]
49. Brodkin, K.; García, A.; Levenston, M. Chondrocyte phenotypes on different extracellular matrix monolayers. Biomaterials 2004,
25, 5929–5938. [CrossRef] [PubMed]
50. Schulze-Tanzil, G.; Mobasheri, A.; Clegg, P.D.; Sendzik, J.; John, T.; Shakibaei, M. Cultivation of human tenocytes in high-density
culture. Histochem. Cell Biol. 2004, 122, 219–228. [CrossRef]
51. Fröhlich, E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomed. 2012, 7,
5577–5591. [CrossRef] [PubMed]
52. Lee, J.; Lilly, G.D.; Doty, R.C.; Podsiadlo, P.; Kotov, N.A. In vitro Toxicity Testing of Nanoparticles in 3D Cell Culture. Small 2009,
5, 1213–1221. [CrossRef]
53. Sun, T.; Jackson, S.; Haycock, J.; MacNeil, S. Culture of skin cells in 3D rather than 2D improves their ability to survive exposure
to cytotoxic agents. J. Biotechnol. 2006, 122, 372–381. [CrossRef]
54. Sowa, M.B.; Chrisler, W.B.; Zens, K.; Ashjian, E.J.; Opresko, L.K. Three-dimensional culture conditions lead to decreased radiation
induced cytotoxicity in human mammary epithelial cells. Mutat. Res. Mol. Mech. Mutagen. 2010, 687, 78–83. [CrossRef] [PubMed]
55. Voigt, N.; Henrich-Noack, P.; Kockentiedt, S.; Hintz, W.; Tomas, J.; Sabel, B.A. Toxicity of polymeric nanoparticles in vivo and
in vitro. J. Nanopart. Res. 2014, 16, 1–13. [CrossRef] [PubMed]
56. Bajpayee, A.G.; Scheu, M.; Grodzinsky, A.J.; Porter, R.M. Electrostatic interactions enable rapid penetration, enhanced uptake and
retention of intra-articular injected avidin in rat knee joints. J. Orthop. Res. 2014, 32, 1044–1051. [CrossRef] [PubMed]
57. Morgen, M.; Tung, D.; Boras, B.; Miller, W.; Malfait, A.-M.; Tortorella, M. Nanoparticles for Improved Local Retention after
Intra-Articular Injection into the Knee Joint. Pharm. Res. 2012, 30, 257–268. [CrossRef]
58. Anselmo, A.C.; Mitragotri, S. Nanoparticles in the clinic: An update. Bioeng. Transl. Med. 2019, 4, e10143. [CrossRef]
59. Aini, H.; Itaka, K.; Fujisawa, A.; Uchida, H.; Uchida, S.; Fukushima, S.; Kataoka, K.; Saito, T.; Chung, U.-I.; Ohba, S. Messenger
RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment. Sci. Rep.
2016, 6, 18743. [CrossRef] [PubMed]
